The Choice between Intravenous and Subcutaneous Immunoglobulins: Aspects for Consideration

Achenbach, Caroline von; Hernandez, Giselle Hevia; Gunten, Stephan von

doi:10.1159/000527655

Cited by 4 publications

(2 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a high-dose therapy, IVIG and SCIG preparations are also used for the treatment of autoimmune and inflammatory disorders ( 1 ). Studies over the period of several decades revealed pleiotropic anti-inflammatory mechanisms of action (MoAs) of polyclonal immunoglobulin preparations ( 15 , 29 ).…”

Section: Diversity – the Added Value Of Polyclonal Immunoglobulin Pre...mentioning

confidence: 99%

“…Polyclonal immunoglobulin (Ig) preparations, administered via intravenous (IVIG) or subcutaneous (SCIG) routes, are successfully used as replacement therapy in immunodeficiencies and for the treatment of select autoimmune or inflammatory disorders ( 1 ). These preparations consist of pooled human IgG derived from the plasma of thousands of donors and in contrast to therapeutic monoclonal antibodies encompass an immense range of reactivities ( 2 , 3 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Antibody diversity in IVIG: Therapeutic opportunities for novel immunotherapeutic drugs

et al. 2023

Self Cite

View full text Add to dashboard Cite

Significant progress has been made in the elucidation of human antibody repertoires. Furthermore, non-canonical functions of antibodies have been identified that reach beyond classical functions linked to protection from pathogens. Polyclonal immunoglobulin preparations such as IVIG and SCIG represent the IgG repertoire of the donor population and will likely remain the cornerstone of antibody replacement therapy in immunodeficiencies. However, novel evidence suggests that pooled IgA might promote orthobiotic microbial colonization in gut dysbiosis linked to mucosal IgA immunodeficiency. Plasma-derived polyclonal IgG and IgA exhibit immunoregulatory effects by a diversity of different mechanisms, which have inspired the development of novel drugs. Here we highlight recent insights into IgG and IgA repertoires and discuss potential implications for polyclonal immunoglobulin therapy and inspired drugs.

show abstract

Section: Diversity – the Added Value Of Polyclonal Immunoglobulin Pre...mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Antibody diversity in IVIG: Therapeutic opportunities for novel immunotherapeutic drugs

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

fSCIG 10% in pediatric primary immunodeficiency diseases: a European post-authorization safety study

Čižnár,

Roderick,

Schneiderova

et al. 2024

Allergy Asthma Clin Immunol

View full text Add to dashboard Cite

Background The safety, tolerability, and immunogenicity of hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG) 10% (dual-vial unit of human immunoglobulin 10% and recombinant human hyaluronidase [rHuPH20]) were assessed in children with primary immunodeficiency diseases (PIDs). Methods This phase 4, post-authorization, prospective, interventional, multicenter study (NCT03116347) conducted in the European Economic Area, enrolled patients aged 2 to < 18 years with a documented PID diagnosis who had received immunoglobulin therapy for ≥ 3 months before enrollment. New fSCIG 10% starters underwent fSCIG 10% dose ramp-up for ≤ 6 weeks (epoch 1) before receiving fSCIG 10% for ≤ 3 years (epoch 2); patients pretreated with fSCIG 10% entered epoch 2 directly. The primary outcome was the number and rate (per infusion) of all noninfectious treatment-related serious and severe adverse events (AEs). Results In total, 42 patients were enrolled and dosed (median [range] age: 11.5 [3–17] years; 81% male; 23 new starters; 19 pretreated). Overall, 49 related noninfectious, treatment-emergent AEs (TEAEs) were reported in 15 patients; most were mild in severity (87.8%). No treatment-related serious TEAEs were reported. Two TEAEs (infusion site pain and emotional distress) were reported as severe and treatment-related in a single new fSCIG 10% starter. The rate of local TEAEs was lower in pretreated patients (0.1 event/patient-year) versus new starters (1.3 events/patient-year). No patients tested positive for binding anti-rHuPH20 antibodies (titer of ≥ 1:160). Conclusions No safety signals were identified, and the incidence of local AEs declined over the duration of fSCIG 10% treatment. This study supports fSCIG 10% long-term safety in children with PIDs. Trial registration number (ClinicalTrials.gov) NCT03116347.

show abstract

Sentiment analysis of subcutaneous and intravenous immunoglobulin therapy: public healthcare perception through social media discourse

Tarango-García,

Rodríguez-Narciso,

Castañeda-Leyva

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

PurposeImmunoglobulin replacement therapy remains a cornerstone of treatment in antibody deficiencies and other inborn errors of immunity. While patient preferences between subcutaneous and intravenous immunoglobulin have been studied through questionnaires, no study has yet explored patient perspectives in a free environment. Therefore, we aimed to conduct a sentiment analysis as well as a temporal and geographical analysis on public opinions obtained from social media to better understand patient satisfaction and public perception on immunoglobulin therapy.MethodsA dataset of 43,700 tweets spanning from the 1st of January of 2012 to the 31st of December of 2022 was obtained. A Valence Aware Dictionary for Sentiment Reasoning sentiment analysis was performed, followed by statistical, geographical and temporal analyses.ResultsMean polarity of intravenous immunoglobulin related tweets was 0.1295 (positive), while mean polarity for subcutaneous immunoglobulin was 0.2117 (positive). Temporal analysis through a statistical model demonstrated that the volume of tweets increased over time for both subcutaneous and intravenous treatment. Geographical analysis revealed that the majority of texts originated from the United States. The highest mean polarity was observed in Romania with a mean value of 0.2966, while the lowest polarity was documented in Norway with a mean of -0.0211.ConclusionTweets linked to subcutaneous immunoglobulin treatment had a higher average polarity, indicating a more positive public perception. The amount of tweets relating to both therapies showed a tendency to increase as the years progressed, implying an increase in public discussion on immunoglobulin treatment.

show abstract

The Choice between Intravenous and Subcutaneous Immunoglobulins: Aspects for Consideration

Cited by 4 publications

References 93 publications

Antibody diversity in IVIG: Therapeutic opportunities for novel immunotherapeutic drugs

Antibody diversity in IVIG: Therapeutic opportunities for novel immunotherapeutic drugs

fSCIG 10% in pediatric primary immunodeficiency diseases: a European post-authorization safety study

Sentiment analysis of subcutaneous and intravenous immunoglobulin therapy: public healthcare perception through social media discourse

Contact Info

Product

Resources

About